CAJ | 학술논문

目的通过银杏苦内酯B(BN52021)对血小板活化因子(PAF)的拮抗作用,探讨BN52021治疗重症急性胰腺炎(SAP)的疗效.方法 Wistar大鼠180只按随机数字表法分为对照组(60只)、SAP组(60只)、BN52021组(60只),每组按不同时相点(1、2、3、6、12、24 h)分为6小组,分别监测血清淀粉酶的变化,用RT-PCR和Western blot法分别监测胰腺组织PAF受体mRNA和蛋白表达的变化,同时对胰腺组织进行病理学观察.多组比较采用单因素方差分析.结果血清淀粉酶和病理学结果显示SAP制模成功,BN52021组血清淀粉酶在3、6、24 h[(4185 ±148)U/L,(3785 ±124)U/L,(1360 ±161)U/L]较SAP组[(4799 ±107)U/L,(4920±140)U/L,(2283±127)U/L]显著降低,病理学评分在3、6、12 h(5.95 ±0.19,5.55 ±0.36,6.72 ±0.30)较SAP组(8.85±0.39,9.15±0.55,10.10±0.65)显著降低;PAF受体mRNA及蛋白检测结果显示,SAP组和BN52021组早期逐渐上升(0.49±0.09～0.71±0.14,0.43±0.06～1.69±0.06),在3 h达到高峰,3组比较差异有统计学意义(F=4.58.6.24,P<0.05).结论 PAF受体在SAP大鼠胰腺组织中表达是动态变化的,PAF受体参与了SAP病情的发生、发展;BN52021可降低SAP血清淀粉酶和改善胰腺组织病理变化,发挥了一定的治疗作用,但对胰腺组织PAF受体的表达无显著影响.
목적 통과은행고내지B(BN52021)대혈소판활화인자(PAF)적길항작용,탐토BN52021치료중증급성이선염(SAP)적료효.방법 Wistar대서180지안수궤수자표법분위대조조(60지)、SAP조(60지)、BN52021조(60지),매조안불동시상점(1、2、3、6、12、24 h)분위6소조,분별감측혈청정분매적변화,용RT-PCR화Western blot법분별감측이선조직PAF수체mRNA화단백표체적변화,동시대이선조직진행병이학관찰.다조비교채용단인소방차분석.결과 혈청정분매화병이학결과현시SAP제모성공,BN52021조혈청정분매재3、6、24 h[(4185 ±148)U/L,(3785 ±124)U/L,(1360 ±161)U/L]교SAP조[(4799 ±107)U/L,(4920±140)U/L,(2283±127)U/L]현저강저,병이학평분재3、6、12 h(5.95 ±0.19,5.55 ±0.36,6.72 ±0.30)교SAP조(8.85±0.39,9.15±0.55,10.10±0.65)현저강저;PAF수체mRNA급단백검측결과현시,SAP조화BN52021조조기축점상승(0.49±0.09～0.71±0.14,0.43±0.06～1.69±0.06),재3 h체도고봉,3조비교차이유통계학의의(F=4.58.6.24,P<0.05).결론 PAF수체재SAP대서이선조직중표체시동태변화적,PAF수체삼여료SAP병정적발생、발전;BN52021가강저SAP혈청정분매화개선이선조직병리변화,발휘료일정적치료작용,단대이선조직PAF수체적표체무현저영향.
Objective To investigate the inhibitory effect of ginkgolide B (BN52021) on severe acute pancreatitis (SAP) via detecting the antagonistic effect of BN52021 on platelet-activating factor (PAF). Methods One hundred and eighty Wistar rats were randomly divided into control group (n = 60), SAP group (n = 60) and BN52021 group (n =60) according to the random number table. The 3 groups were divided into 6 subgroups at different time points after operation (1 h, 2 h, 3 h, 6 h, 12 h, and 24 h). The changes of serum amylase in each group were monitored. The expression of platelet-activating factor receptor (PAFR) mRNA and protein was detected by RT-PCR and Western blot, and the pathological changes of pancreatic tissues were observed. All the data were analyzed by one-way ANOVA. Results Serum amylase level and pathological results showed that it was successful in preparing SAP model. The serum amylase levels at postoperative hour 3, 6 and 24 were (4185 ±148) U/L, (3785 ± 124) U/L and (1360 ± 161) U/L in BN52021 group, which were significantly lower than those in SAP group [(4799 ± 107) U/L, (4920 ± 140) U/L, (2283 ± 127) U/L)]. The pathological scores at postoperative hour 3, 6, 12 were 5.95±0. 19, 5.55±0.36, 6.72±0. 30 in BN52021 group, which were significantly lower than those in SAP group (8.85 ± 0.39, 9.15 ± 0.55, 10.10 ±0. 65). The mRNA and protein expression of PAFR were gradually increased at the early stage (0.49 ± 0.09-0.71 ± 0.14 vs 0. 43 ～ O. 06-1.69 ± 0.06), and reached peak at postoperative hour 3. The expression levels of PAFR mRNA and protein in BN52021 group and SAP group at postoperative hour 3 had statistical difference among the 3 groups (F = 4.58, 6.24, P < 0.05). Conclusions The expression of PAFR mRNA and protein in the pancreatic tissue of SAP rats is dynamically changing. PAFR plays an important role in the occurrence and progression of SAP. BN52021 can reduce the expression of serum amylase and improve the pancreatic pathological changes, but it has no effect on the expression of PAFR in pancreatic tissue.